Management Team
Michael S. Perry, DVM, Ph.D., FRCVS
President and Chief Medical Officer
Michael S. Perry was appointed President and Chief Medical Officer in February 2010. Dr. Perry has been a consultant to the company since September 2009 and is a Venture Partner with Bay City Capital LLC (since November 2005). He was Chief Development Officer at VIA Pharmaceuticals, Inc., a publicly held drug development company, from April 2005 until May 2009. Prior thereto, he served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from June 2003 to April 2005. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter BioScience. From 1997 to 2000, Dr. Perry was President and Chief Executive Officer of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp., and from 1994 to 1997, he was Vice President of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals). Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Pharmacology and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is also a graduate of the International Management Program at Harvard Business School.
Michael K. Jackson
Interim Chief Financial Officer
Michael K. Jackson was appointed interim Chief Financial Officer in August 2010. Mr. Jackson also is Controller of the Company (since 2003) and, prior to his appointment as Interim Chief Financial Officer, served as Senior Director, Finance of the Company (since 2008). Prior to joining the Company, Mr. Jackson served as Controller for Xylo, Inc., an internet development company, from 2001 to 2003 and as Director, Finance Operations at Spacelabs Medical, a public medical device company, from 1998 to 2001. From 1992 to 1998, Mr. Jackson served as Controller for Ride, Inc., a public recreational consumer products company. Prior to that, Mr. Jackson served in increasingly senior finance and accounting roles with high technology firms, Ernst & Young and Price Waterhouse. Mr. Jackson is a certified public accountant and received his M.B.A in finance and B.S. in mathematics from Brigham Young University.
Cheni Kwok, Ph.D., CLP
Senior Vice President, Corporate Development
Cheni Kwok joined Poniard as the Vice President of Business Development in July 2006. Previously, Dr. Kwok was Director of Business Development at Celera Genomics from 2004 to 2006, where she led the business development efforts for Celera's small molecule therapeutics programs. Prior to Celera, Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc. from 2000 to 2004, where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham Pharmaceuticals from 1997 to 2000. She received a bachelor's degree in biotechnology from Imperial College of Science, Technology and Medicine, University of London, U.K. and a Ph.D. in human molecular genetics from the University of Cambridge, U.K. Dr. Kwok obtained the Certified Licensing Professional (CLP™) credential established by the Licensing Executives Society (USA and Canada).
Anna Lewak Wight, J.D., CLP
Vice President, Legal and Corporate Secretary
Anna Lewak Wight joined the company in 1994. Previously, she was an equity partner in the law firm of Morrison & Foerster, managing its Seattle intellectual property practice from 1993 to 1994. Prior to Morrison & Foerster, Ms. Wight was also an equity partner in the intellectual property law firm of Harness, Dickey and Pierce, where she practiced from 1986 to 1993, and established and chaired the Biotechnology and Medical Arts Group. Ms. Wight has worked on many high-profile biotechnical and biomedical projects for academic and research institutions, including gene therapy for cystic fibrosis and neurofibromatosis and CD28 immunoregulation. She received a J.D. from Wayne State University Law School and an M.S. from the Genetics Program at Michigan State University. She also obtained the Certified Licensing Professional (CLP™) credential established by the Licensing Executives Society (USA and Canada).
|
